RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Boregowda, Rajeev K; Olabisi, Oyenike O; Abushahba, Walid; Jeong, Byeong-Seon; Haenssen, Keneshia K; Chen, Wenjin; Chekmareva, Marina; Lasfar, Ahmed; Foran, David J; Goydos, James S; Cohen-Solal, Karine A

People

Help

CiteReady is an online personal knowledge management tool. Click to find out more!

James's Profile

James's Publications

Publicly Shared Collections

Shared by James Goydos

My Publications

Updated in 8/12/2020 12:05:33 PM

Viewed: 192 times

(Journal Article)

Cancer letters 348 (1-2): 61-70 (2014)

RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Rajeev K Boregowda , Oyenike O Olabisi , Walid Abushahba , Byeong-Seon Jeong , Keneshia K Haenssen , Wenjin Chen , Marina Chekmareva , Ahmed Lasfar , David J Foran , James S Goydos , Karine A Cohen-Solal

ABSTRACT
In the present study, we investigated the role of the transcription factor RUNX2 in melanomagenesis. We demonstrated that the expression of transcriptionally active RUNX2 was increased in melanoma cell lines as compared with human melanocytes. Using a melanoma tissue microarray, we showed that RUNX2 levels were higher in melanoma cells as compared with nevic melanocytes. RUNX2 knockdown in melanoma cell lines significantly decreased Focal Adhesion Kinase expression, and inhibited their cell growth, migration and invasion ability. Finally, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration.

DOI: 10.1016/j.canlet.2014.03.011

ISSN: 0304-3835

Report this

Community
People

Position:	Professor
About me:	James Goydos, MD is widely recognized as an expert in melanoma research & surgical oncology. In his over 20 years of experience as a surgeon, he has conducted research that has translated into patient care, clinical trials, & cutting-edge treatment. His research and clinical trials have recorded growth arrest in melanoma cells, transforming the area of cancer genomics. Goydos has decades of experience as a Professor of Surgery and researcher at UMDNJ Robert Wood Johnson Medical School. He is an advocate for patient privacy and is recognized for leadership in patient care by the Cancer Institute of New Jersey and MRF. By 2020, his work in melanoma & innovative trials have led him to record numerous awards by Castle Connolly. He has helped individuals to better understand the mechanics of melanoma, the invasion of the dermis, and to see that it is not always a death sentence.
ORCID: